Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 29, 2020 8:00 AM - Jul 03, 2020 6:00 PM

(W. Europe Standard Time)

4051 Basel, Switzerland

DIA EUROPE 2020

Biologicals and Biosimilars – Science versus Regulation

Session Chair(s)

Helga  Gardarsdottir, PhD

Helga Gardarsdottir, PhD

Associate Professor

Utrecht University, Netherlands

Christine  Hallgreen, DrSc, PhD

Christine Hallgreen, DrSc, PhD

Associate Professor

University of Copenhagen, Denmark

This session will explore the interplay between science and regulation in the field of biologicals and biosimilars. What are the different perceptions on scientific requirements for regulatory decision-making on biosimilars? How do biological guidelines influence scientific publication of quality attributes for similarity? Are there any differences between scientific and regulatory reporting on biological safety? Three young regulatory scientists will present their most recent findings, followed by reflections from industry and academia on ways forward. The audience is encouraged to fuel the debate.

Learning Objective : Participants will be able to: - Describe the current regulatory framework for biosimilars in the EU - Differentiate different perceptions on the EU requirement for comparability clinical trials as part of establishing biosimilarity - Share their thoughts on and propose their inputs on the way forward for the EU requirement for comparability clinical trials for biosimilars

Speaker(s)

Louise C.  Druedahl, PhD, MPharm

Can we go for less? Assessing perceptions of EU requirements for comparability clinical trials for biosimilars

Louise C. Druedahl, PhD, MPharm

Centre for Advanced Studies in Biomedical Innovation Law (CeBIL), Denmark

Faculty of Law

Ali Mohammed Alsamil, MSc

Reporting of quality attributes in similarity assessments of (intended) biosimilars in scientific publications

Ali Mohammed Alsamil, MSc

Utrecht University, Netherlands

PhD Candidate

Lotte  Minnema, MPharm

Safety Information of Biologicals for Multiple Sclerosis: A Comparison between Information Originating from Regulators and Scientific Safety Publications

Lotte Minnema, MPharm

Utrecht University/Medicines Evaluation Board, Netherlands

PhD candidate/pharmacovigilance assessor

Virginia  Acha, PhD, MSc

Panelist

Virginia Acha, PhD, MSc

Merck Sharp & Dohme LLC, United Kingdom

AVP, Global Regulatory Policy

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.